ADVENTRX Pharmaceuticals Receives Designation as a Small/Medium Enterprise by the European Medicines Agency
June 07 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, June 7 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
announced today that the Company, through its wholly owned
subsidiary, ADVENTRX (Europe) Ltd., has received notification from
the European Medicines Agency (EMEA) that it has been granted
designation as a Small/Medium Enterprise (SME). Implemented in
November 2005, the SME program is an initiative by the EMEA that is
designed to assist small companies applying for European approval
of medicinal products. In addition to financial benefits afforded
the designation through lowered or reduced fees, the designation
offers participants access to substantial scientific advice during
the clinical development and application processes. "We are pleased
to have been granted designation as a Small/Medium Enterprise and
look forward to the advice and administrative assistance of the
EMEA as we continue to pursue clinical development opportunities in
the European Union," stated Evan M. Levine, chief executive of
ADVENTRX. ADVENTRX (Europe) Ltd. was incorporated in July 2004 in
the United Kingdom as a wholly-owned subsidiary of ADVENTRX
Pharmaceuticals, Inc., primarily to facilitate conducting clinical
trials in the European Union. Additional information on the SME
program is available from the EMEA website at:
http://www.emea.eu.int/SME/SMErelated.htm. About ADVENTRX
Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on commercializing
proprietary product candidates for the treatment of cancer and
infectious diseases. The Company seeks to improve the performance
and safety of existing treatments by addressing significant
problems such as drug metabolism, bioavailability, excessive
toxicity and treatment resistance. More information can be found on
the Company's web site at http://www.adventrx.com/. Forward Looking
Statement ADVENTRX cautions you that statements included in this
press release that are not a description of historical facts are
forward-looking statements that involve risks and assumptions that,
if they materialize or do not prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or
those expressed or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to:
uncertainties inherent in the drug development process; the timing
and success of clinical trials; the validity of research results;
the receipt of necessary approvals from the FDA and other
regulatory agencies; and other risks and uncertainties more fully
described in ADVENTRX's press releases and public filings with the
Securities and Exchange Commission. ADVENTRX's public filings with
the Securities and Exchange Commission are available at
http://www.sec.gov/. ADVENTRX does not intend to update any
forward-looking statement, including as set forth in this press
release, to reflect events or circumstances arising after the date
on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc.
CONTACT: Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866
Web site: http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024